The In Vitro Effects of Antithrombin III on the Activated Coagulation Time in Patients on Heparin Therapy

2000 ◽  
Vol 90 (5) ◽  
pp. 1076-1079 ◽  
Author(s):  
Jerrold H. Levy ◽  
Felix Montes ◽  
Fania Szlam ◽  
Christopher D. Hillyer
1991 ◽  
Vol 66 (02) ◽  
pp. 213-217 ◽  
Author(s):  
Arthur P Bode ◽  
William J Castellani ◽  
Edna D Hodges ◽  
Susan Yelverton

SummaryThe effect of lysed platelets on the activated coagulation time (ACT) was studied in heparinized whole blood during titration with protamine. Frozen-thawed washed platelet suspension, or a chromatography fraction thereof, or autologous frozen-thawed platelet-rich plasma was added in various dilutions to freshly drawn blood anticoagulated with 3,000 USP units/1 heparin. After a 10 min incubation, the amount of protamine needed to restore the ACT to baseline ("protamine titration dose") was determined. We found that the protamine titration dose decreased in proportion to the amount of lysed platelet material added; expressed as a percentage of the total number of platelets present, each unit increase in lysed platelets produced a 1.7% ±0.8 (SD) reduction in the protamine dose needed to normalize the ACT. A heparin activity assay showed that this effect was not due to antiheparin activity of lysed platelets such as platelet factor 4 (PF4). Our data indicate that the procoagulant activity of platelet membranes reduced the sensitivity of the ACT to heparin. These findings suggest that membranous platelet microparticles may cause an inaccurate calculation, based on the ACT, of a protamine dose to reverse heparin anticoagulation in cardiopulmonary bypass procedures.


1981 ◽  
Author(s):  
Harry L Messmore ◽  
Jawed Fareed ◽  
Zaheer Parvez ◽  
Judith M Kniffin ◽  
Grace Squillaci ◽  
...  

Although heparin-induced thrombocytopenia is a well recognized complication of heparin therapy (low dose or therapeutic), the mechanisms involved remain to be clarified. We have studied the serum (heated to 56°C for 30min) and platelets of patients who became thrombocytopenic while receiving treatment with beef lung heparin. The in-vitro aggregation of these platelets in their own platelet rich plasma (PRP) occurred equally well with porcine mucosal (Na+ and Ca++ salts), sheep mucosal (Na+ salt) and beef lung heparins. In-vitro aggregation also occurred with low molecular weight (4-8 × 103 daltons) porcine heparin fractions. Normal PRP aggregated readily with each of these heparins when patient serum was present. We also found that the release reaction occurs as measured by luciferase coupled luminescense aggregometry. This reaction was only slightly less when aspirin-treated platelets were used. Electron microscopy of platelets aggregated with patient serum and heparin revealed intact ghosts which showed morphology identical to collagen-treated platelets after release has occurred. This activity can be removed from the patient serum with protein A-sepharose column, and can be eluted off the column with 1M acetic acid. Heparin fragments (MW 1-2 × 103 daltons) retain potent anti-Xa activity mediated through antithrombin-III. These fragments do not aggregate the platelets of PRP in the presence of patient or control serum. This suggests the possibility that ultralow MW heparin would not cause thrombocytopenia in a patient who developed it while on high MW heparin, but this remains to be proven, and individual reactions may vary.


1981 ◽  
Author(s):  
B A Bradlow ◽  
P M Atkinson ◽  
M Rebello ◽  
M C Gaillard

The coagulant action of Dispholidus typus venom was relatively resistant to inhibition by heparin in vitro. Heparin concentrations that inhibited coagulation due to either intrinsic pathway or Russell’s viper venom activation had little effect on coagulation due to D. Typus venom. At very high heparin to venom ratios, similar to ratios attainable in vivo this resistance could be overcome. The resistance could not be attributed to an abnormal thrombin produced by the venom since the thrombin produced from purified prothrombin by venom action reacted similarly to the thrombin produced by Factor Xa activation with purified antithrombin III. Thrombin produced from whole plasma by venom action also reacted similarly to physiological thrombin with antithrombin III in a crossed immunoelectrophoresis system. Incubation of venom with heparin and with antithrombin III did not alter the activities of these inhibitors. The heparin resistance may therefore be due to the fact that the venom is a direct activator of prothrombin. In vivo studies in rabbits indicated that heparin administered simultaneously with venom delayed the onset and reduced the severity of disseminated intravascular coagulation. Heparin administered later was much less effective. Early heparin therapy may be of value in human victims when specific antivenom is not available.


1975 ◽  
Vol 34 (03) ◽  
pp. 748-762 ◽  
Author(s):  
Ewa Marciniak

SummaryThrombin, while reacting in the presence of heparin, impairs the inhibitory capacity of antithrombin III so that subsequent inhibition of thrombin or factor Xa is decreased or abolished. This adverse effect of heparin has been observed directly with at least 1.5 Iowa units of thrombin per each unit of purified human antithrombin III participating in the reaction. The inhibitory capacity was then totally destroyed and some residual thrombin remained in the active form. With a lower enzyme/inhibitor ratio inactivation of thrombin in the presence of heparin was fast and complete, however, a significant decrease of inhibitory capacity below that found in reaction without heparin, has been established by measuring the residual antithrombin III activity. In defibrinated human plasma at least 2 units of thrombin per each antithrombin III unit were required to demonstrate directly the adverse effect of heparin, but a fast depletion of inhibitory capacity has been also observed after repeated additions of small thrombin portions into plasma heparinized in vitro or in vivo. Portions of enzyme initially added disappeared with great velocity; subsequent portions, however, accumulated building up a high thrombin level not seen in the absence of heparin. The accumulation of residual enzyme was more extensive in plasma containing about 1 heparin unit per ml than anticoagulant at lower concentrations and was particularly noticeable in antithrombin III deficient plasma. These results may have some bearings on the approach to heparin therapy in the event when thrombin continuously generates or when a marked deficiency of antithrombin III exists.


Sign in / Sign up

Export Citation Format

Share Document